Diffuse large B-cell lymphoma (DLBCL) exhibits frequent inactivating mutations of the
histone acetyltransferase CREBBP, highlighting the attractiveness of targeting CREBBP deficiency as a therapeutic strategy. In this study, we demonstrate that
chidamide, a novel
histone deacetylase (
HDAC) inhibitor, is effective in treating a subgroup of relapsed/refractory DLBCL patients, achieving an overall response rate (ORR) of 25.0% and a complete response (CR) rate of 15.0%. However, the clinical response to
chidamide remains poor, as most patients exhibit resistance, hampering the clinical utility of the
drug. Functional in vitro and in vivo studies have shown that CREBBP loss of function is correlated with
chidamide sensitivity, which is associated with modulation of the cell cycle machinery. A combinatorial
drug screening of 130
kinase inhibitors targeting cell cycle regulators identified
AURKA inhibitors, which inhibit the G2/M transition during the cell cycle, as top candidates that synergistically enhanced the antitumor effects of
chidamide in CREBBP-proficient DLBCL cells. Our study demonstrates that CREBBP inactivation can serve as a potential
biomarker to predict
chidamide sensitivity, while combination of an
AURKA inhibitor and
chidamide is a novel therapeutic strategy for the treatment of relapsed/refractory DLBCL.